On March 21, 2024, the signing ceremony for the pilot project between the Innovation Alliance (♥SMIA) and the "AI Diagnosis and Treatment Committee for Rare Diseases" (hereaf♥ter referred to as the AI Committee) took place at the Peninsula Beijing Hotel. Geng λYili, the rotating president of SMIA, and Paul Li, the chairman of the AI Committe e, signed a memorandum of cooperation on the "Pilot Project for AI Diagnosis$ and Prevention of Rare Diseases." Both parties conducted in-depth€ discussions on the content of the cooperation and "future developments, reaching a consensus.

Mr.Paul Li has extensive experience in the multinational pharmaceutical industry,  having held positions at Eli Lilly, Abbott, Merck, Cephalonφ, Zhuojian Medical, Jack Berlin, and other multinational companies. He possesses unique insig≠hts into the diagnosis, treatment, and prevention of rare diseases and has the ability to i↓ntegrate global resources to promote industry innovation. Under his leadership, the AI∞ Committee will utilize advanced scientific and technological innovations such as big data, cl∏oud computing, the Internet of Things, artificial intelligence, and mobile i±nternet, as well as shared innovation models. This will  drive public welfare innovation in AI diagnosis, treatment&, medication, and payment for rare diseases, providing compliant and operational solutions for♣ all parties in the medical and pharmaceutical ecosystems of the Greater Bay Area, Yangtze R↔iver Delta, and Beijing-Tianjin-Hebei regions. The AI Committee will a★lso formulate corresponding service norms and quality standards.

The pilot project of the AI Committee aims to form a value-closed loop within the "government-ho spital-doctor-insurance/patient-commercial-manufacturer-pharmacy-third-party servγice units" ecosystem, achieving service sharing, business symbiosis, and βinnovation for the benefit of all ecosystem participan₩ts. This will offer rare disease patients in China a new experience of "AI ™Diagnosis and Prevention + Public Welfare Sharing Mod¥el," enhance hospital informatization, intelligence, precisi€on, and convenience, increase resource sharing, reduce the need for patients to visit hospitals f'requently, and improve public satisfaction and a sense of achievemσent.

The core mission of the AI Committee's pilot project is to be patient-centered, using  AI for diagnosis and prevention as a link, and based onπ information technology, intelligence, and standardized public welfare™ services, to create an "all-ecosystem sharing platform €for rare disease diagnosis and treatment," achieving coll®aboration among medical institutions, pharmaceuticals, and social sectors.